Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women

References

• Fugate Woods N, Sullivan Mitchell E. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005;118:14–24S
   PubMed Web of Science ®Google Scholar
• Gold EB, Colvin A, Avis N, . Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226–35
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJIII. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763–73
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Fast facts on osteoporosis. http://www.nof.org/node/40 [serial online]; Accessed November 17, 2011
   Google Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978
   PubMedGoogle Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17: 242–55
   PubMed Web of Science ®Google Scholar
• Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274–7
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA, . Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–7
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Kopher RA, DeFor TA, Kelley ME. Hormone use and patient concerns after the findings of the Women's Health Initiative. Menopause 2005;12:399–404
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084–91
   PubMed Web of Science ®Google Scholar
• Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008;15:984–92
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045–52
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, . Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025–38
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039–44
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018–24
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116–24
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• Lobo RA, Belisle S, Creasman WT, . Should symptomatic menopausal women be offered hormone therapy?MedGenMed 2006;8:40
   PubMedGoogle Scholar
• Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329–35
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Chines AA, Racketa J, Mirkin S. Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women. Menopause 2010;17:1237–8
   Web of Science ®Google Scholar
• Prior JC, Nielsen JD, Hitchcock CL, Williams LA, Vigna YM, Dean CB. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007;112: 517–25
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999;44:286–96
   PubMed Web of Science ®Google Scholar
• Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118:117–24
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897–903
   PubMed Web of Science ®Google Scholar
• Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 2009;23:75–85
   Google Scholar
• Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/ conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010;13: 132–40
   PubMed Web of Science ®Google Scholar